Skip to main content
HLB bioStep Co.,Ltd. logo

HLB bioStep Co.,Ltd. — Investor Relations & Filings

Ticker · 278650 ISIN · KR7278650007 KO Professional, scientific and technical activities
Open in API
Filings indexed 323 across all filing types
Latest filing 2026-03-25 Investor Presentation
Country KR South Korea
Listing KO 278650

About HLB bioStep Co.,Ltd.

http://hlbbiostep.com/en/

HLB bioStep Co.,Ltd. is a non-clinical Contract Research Organization (CRO) that provides a range of testing services to pharmaceutical companies and bio ventures. The company's core services support new drug development and include efficacy testing, pharmacokinetic/toxicokinetic (PK/TK) studies, and toxicology evaluations. A key area of specialization is veterinary medicine; HLB bioStep is an institution approved to conduct non-clinical tests and clinical trials for veterinary drugs. It also offers consulting services for regulatory approval procedures. The company utilizes various platform technologies, such as cell-enzyme-based screening and xenograft assays, and provides a comprehensive 'One-Stop Service' that leverages its experience in building laboratory facilities.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Investor Presentation Classification · 80% confidence The document is an announcement for a corporate investor relations event (“기업설명회(IR) 개최”) detailing date, time, venue, participants, purpose, content, and IR material posting. This clearly corresponds to an investor presentation notice rather than financial results or regulatory filings. Hence it is classified as an Investor Presentation (Code: IP).
2026-03-25 Korean
기업설명회(IR)개최
Investor Presentation Classification · 90% confidence The document is a notice of an upcoming corporate investor relations meeting (기업설명회(IR)) with details on date, time, venue, participants, agenda, and where IR materials will be posted. It is announcing an investor presentation event rather than financial results, a regulatory filing, or an annual/interim report. Therefore it matches the ‘Investor Presentation’ category (Code: IP).
2026-03-25 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by HLB BioStep. It contains detailed financial tables including consolidated and separate financial statements, audit opinions, and financial ratios. While it provides financial data, it is a regulatory filing specifically announcing the submission of the audit report to the exchange, rather than the full 10-K annual report document itself. Therefore, it is classified as an Audit Report / Information document. FY 2025
2026-03-18 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for HLB BioStep Co., Ltd. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements rather than the full narrative of company activities, and it is not an announcement (RPA) because it contains the full financial data. FY 2025
2026-03-18 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (DART system) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains the agenda, proxy solicitation details, and financial statements as reference material for the meeting. This falls under the category of Proxy Solicitation & Information Statement.
2026-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for HLB Biostep. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, changes to the articles of incorporation, and director/auditor compensation limits. It also includes detailed management information, such as board activity reports and financial summaries, which are standard components of proxy materials sent to shareholders to solicit votes. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2026-03-11 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.